WO2021011614A1
|
|
Methods for treating or preventing asthma by administering an il-4r antagonist
|
WO2020252214A1
|
|
Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis
|
WO2020247461A1
|
|
Compositions and methods for treating pain in subj ects with rheumatoid arthritis
|
US2021000949A1
|
|
Methods for treating or preventing asthma by administering an il-33 antagonist
|
US2020405851A1
|
|
Method of diagnosis and treatment of rheumatoid arthritis
|
TW202043285A
|
|
Compositions and methods for treating juvenile idiopathic arthritis
|
CA3092936A1
|
|
Use of pcsk9 inhibitor for reducing cardiovascular risk
|
US2019169299A1
|
|
Methods for treating or preventing asthma by administering an il-4r antagonist
|
TW201904608A
|
|
Method for treating hyperlipemia in diabetic patients by administering PCSK9 inhibitor
|
US2019031774A1
|
|
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
HK1243716A1
|
|
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
ZA201700195B
|
|
Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
|
HK1225635A1
|
|
Compositions for the treatment of rheumatoid arthritis and methods of using same
|
SG10202004083UA
|
|
Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
|
CA3003874A1
|
|
Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
|
EP3216461A1
|
|
Compositions and methods for treating rheumatoid arthritis
|
MX2017006286A
|
|
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist.
|
CA2955294A1
|
|
Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
|
WO2016011260A1
|
|
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
EP3770173A1
|
|
Compositions for the treatment of rheumatoid arthritis and methods of using same
|